These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15364412)

  • 1. Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice.
    Tucker HM; Simpson J; Kihiko-Ehmann M; Younkin LH; McGillis JP; Younkin SG; Degen JL; Estus S
    Neurosci Lett; 2004 Sep; 368(3):285-9. PubMed ID: 15364412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology.
    Vepsäläinen S; Hiltunen M; Helisalmi S; Wang J; van Groen T; Tanila H; Soininen H
    Neurosci Lett; 2008 Jun; 438(2):216-20. PubMed ID: 18455870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease.
    Lee JY; Kweon HS; Cho E; Lee JY; Byun HR; Kim DH; Kim YH; Han PL; Koh JY
    Neurosci Lett; 2007 Aug; 423(1):82-7. PubMed ID: 17662525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.
    Kranenburg O; Bouma B; Gent YY; Aarsman CJ; Kayed R; Posthuma G; Schiks B; Voest EE; Gebbink MF
    Mol Cell Neurosci; 2005 Mar; 28(3):496-508. PubMed ID: 15737740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms.
    Cacquevel M; Launay S; Castel H; Benchenane K; Chéenne S; Buée L; Moons L; Delacourte A; Carmeliet P; Vivien D
    Neurobiol Dis; 2007 Aug; 27(2):164-73. PubMed ID: 17566751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
    Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
    Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.
    Van Nostrand WE; Porter M
    Biochemistry; 1999 Aug; 38(35):11570-6. PubMed ID: 10471309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention.
    Eckman EA; Eckman CB
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1101-5. PubMed ID: 16246055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.
    Caccamo A; Oddo S; Sugarman MC; Akbari Y; LaFerla FM
    Neurobiol Aging; 2005 May; 26(5):645-54. PubMed ID: 15708439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrillar prion peptide PrP(106-126) treatment induces Dab1 phosphorylation and impairs APP processing and Abeta production in cortical neurons.
    Gavín R; Ureña J; Rangel A; Pastrana MA; Requena JR; Soriano E; Aguzzi A; Del Río JA
    Neurobiol Dis; 2008 May; 30(2):243-54. PubMed ID: 18374587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.
    Pihlaja R; Koistinaho J; Malm T; Sikkilä H; Vainio S; Koistinaho M
    Glia; 2008 Jan; 56(2):154-63. PubMed ID: 18004725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
    Mohmmad Abdul H; Sultana R; Keller JN; St Clair DK; Markesbery WR; Butterfield DA
    J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo.
    Madani R; Poirier R; Wolfer DP; Welzl H; Groscurth P; Lipp HP; Lu B; El Mouedden M; Mercken M; Nitsch RM; Mohajeri MH
    J Neurosci Res; 2006 Dec; 84(8):1871-8. PubMed ID: 16998901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor.
    Elder GA; Cho JY; English DF; Franciosi S; Schmeidler J; Sosa MA; Gasperi RD; Fisher EA; Mathews PM; Haroutunian V; Buxbaum JD
    J Neurochem; 2007 Aug; 102(4):1220-31. PubMed ID: 17472705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade.
    Dolev I; Michaelson DM
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13909-14. PubMed ID: 15365176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.